Clinical Trial Update: Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl [Phase 4]

View source ↗

Summary

This Phase 4 trial assesses the proportion of depressed outpatients who are poor metabolizers of extended-release venlafaxine hydrochloride.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Effexor XR (venlafaxine hydrochloride) extended-release (venlafaxine hydrochloride)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Depression | Phase 4 | Status: COMPLETED